Bladder cancer biomarker discovery using global metabolomic profiling of urine

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wittmann, Bryan M ^a   Stirdivant, Steven M ^a   Mitchell, Matthew W ^a   Wulff, Jacob E ^a   McDunn, Jonathan E ^a   Li, Zhen ^a   Dennis Barrie, Aphrihl ^b   Neri, Bruce P ^a   Milburn, Michael V ^a   Lotan, Yair ^b   Wolfert, Robert L ^a  

^a METABOLON INC   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRIC ACID; 3 HYDROXYBUTYRIC ACID; 4 AMINOBUTYRIC ACID; ACETYLCARNITINE; ADENOSINE; ADIPIC ACID; ANSERINE; ARACHIDONIC ACID; BETA HYDROXYPYRUVATE; BIOLOGICAL MARKER; FRUCTOSE; GLUCONIC ACID; GUANIDINOACETIC ACID; GULONO 1,4 LACTONE; HYDROXYACID; ISOLEUCINE; LACTIC ACID; LACTONE DERIVATIVE; LEUCINE; LIPID; PALMITOYL SPHINGOMYELIN; PHOSPHORYLCHOLINE; PYRIDOXIC ACID; PYRUVIC ACID DERIVATIVE; SPHINGOMYELIN; SUCCINIC ACID; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; XANTHURENIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLADDER CANCER; CANCER STAGING; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; PATIENT CARE; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; CASE CONTROL STUDY; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS; URINE;

AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84919884328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115870     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, et al. (2012) Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann Oncol 23: 2352-2356.
3. Scher H, Bahnson R, Cohen S, Eisenberger M, Herr H, et al. (1998) NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 12: 225-271.
4. van der Poel HG, Debruyne FM (2001) Can biological markers replace cystoscopy? An update. Curr Opin Urol 11: 503-509.
5. Gaston KE, Pruthi RS (2004) Value of urinary cytology in the diagnosis and management of urinary tract malignancies. Urology 63: 1009-1016.
6. van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, et al. (2009) Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. European Urology 56: 430-442.
7. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59: 997-1008.
8. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, et al. (2013) EAU guidelines on non-muscle- invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64: 639-653.
9. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, et al. (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178: 2314-2330.
10. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, et al. (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186: 2158-2167.
11. Sengupta S, Blute ML (2006) The management of superficial transitional cell carcinoma of the bladder. Urology 67: 48-55.
12. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330.
13. Shore ND, Fernandez CA, Shuber AP (2012) Noninvasive multianalyte diagnostic assay for monitoring bladder cancer recurrence. Res Rep Urol 4: 49-56.
14. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, et al. (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117: 5392-5401.
15. Chen T, Xie G,Wang X, Fan J, Qiu Y, et al. (2011) Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 10: M110 004945.
16. Ganti S, Weiss RH (2011) Urine metabolomics for kidney cancer detection and biomarker discovery. Urologic oncology 29: 551-557.
17. Kim K, Taylor SL, Ganti S, Guo L, Osier MV, et al. (2011) Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 15: 293-303.
18. Milburn M, Lawton K, McDunn J, Ryals J, Guo L (2012) Understanding Cancer Metabolism Through Global Metabolomics. In: Suhre K, editor. Genetics Meets Metabolomics: Springer New York. pp. 177-190.
19. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, et al. (2011) Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. Cancer Research 71:7376-7386.
20. Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, et al. (2008) Detection of Bladder Cancer in Human Urine by Metabolomic Profiling Using High Performance Liquid Chromatography/Mass Spectrometry. J Urol 179: 2422-2426.
21. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, et al. (2010) Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer. J Proteome Res 9: 2988-2995.
22. Srivastava S, Roy R, Singh S, Kumar P, Dalela D, et al. (2010) Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by ∧{1}H NMR spectroscopy. Cancer Biomarkers 6: 11-20.
23. Huang Z, Lin L, Gao Y, Chen Y, Yan X, et al. (2011) Bladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approach. Molecular & Cellular Proteomics 10.
24. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E (2009) Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81: 6656-6667.
25. Team RC (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna Austria.
26. Breiman L (2001) Random Forests. Machine Learning 45: 5-32.
27. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, et al. (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12: 77.
28. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
29. Cairns RA, Mak TW (2013) Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities. Cancer Discovery 3: 730-741.
30. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, et al. (2013) The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15: 491-501.
31. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
32. Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, et al. (2012) Kidney Tumor Biomarkers Revealed by Simultaneous Multiple Matrix Metabolomics Analysis. Cancer Research 72: 3471-3479.
33. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, et al. (2013) Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121: 4917-4924.
34. McDunn JE, Li Z, Adam KP, Neri BP, Wolfert RL, et al. (2013) Metabolomic signatures of aggressive prostate cancer. Prostate 73: 1547-1560.
35. Hsu PP, Sabatini DM (2008) Cancer Cell Metabolism: Warburg and Beyond. Cell 134: 703-707.
36. Levine AJ, Puzio-Kuter AM (2010) The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes. Science 330: 1340-1344.
37. Kaelin WG, Thompson CB (2010) Q&A: Cancer: Clues from cell metabolism. Nature 465: 562-564.
38. Mazurek S (2011) Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. The International Journal of Biochemistry & Cell Biology 43: 969-980.
39. Linardic CM, Hannun YA (1994) Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J Biol Chem 269: 23530-23537.
40. Chatterjee S, Han H, Rollins S, Cleveland T (1999) Molecular cloning, characterization, and expression of a novel human neutral sphingomyelinase. J Biol Chem 274: 37407-37412.
41. Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW (1984) The Role of Arachidonic Acid Oxygenation Products in Pain and Inflammation. Annual Review of Immunology 2: 335-357.
42. Holeček M (2002) Relation between glutamine, branched-chain amino acids, and protein metabolism. Nutrition 18: 130-133.
43. Tonjes M, Barbus S, Park YJ, Wang W, Schlotter M, et al. (2013) BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat Med 19: 901-908.
44. Landaas S, Pettersen JE (1975) Clinical conditions associated with urinary excretion of 2- hydroxybutyric acid. Scand J Clin Lab Invest 35: 259-266.
45. Mitchell GA, Kassovska-Bratinova S, Boukaftane Y, Robert MF, Wang SP, et al. (1995) Medical aspects of ketone body metabolism. Clin Invest Med 18: 193-216.
46. Schroeder MA, Atherton HJ, Dodd MS, Lee P, Cochlin LE, et al. (2012) The cycling of acetylcoenzyme A through acetylcarnitine buffers cardiac substrate supply: a hyperpolarized 13C magnetic resonance study. Circ Cardiovasc Imaging 5: 201-209.
47. Wallace DC (2012) Mitochondria and cancer. Nat Rev Cancer 12: 685-698.